FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
|Articles|January 17, 2019
Locate Bio to be Granted Key US and EU Patents for its Gene Delivery Tech
Author(s)BioPharm International Editors
Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe
Advertisement
Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe, in a Jan. 7, 2019
IntraStem is a non-viral gene delivery technology that is based on cell penetrating peptides. The intracellular delivery system has been designed to overcome the limitations of current gene therapy vectors. Additionally, as a next-generation approach, the system is capable of delivering a variety of biologics, such as plasmid DNA, mRNA, siRNA, proteins, and antibodies, in various cell types, including hard-to-transfect cells.
“The granting of our first IntraStem patents in the US and Europe adds to the excitement building around our next generation, non-viral transfection technology,” commented Nick Staples, CEO of Locate, in a Jan. 7, 2019
Source:
Advertisement
Related to this article
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5